Weekly roundup

Here’s what you missed last week!

🏛️ Policy & Payers

  • Prior auth relief may be on the horizon as 93% of health plan executives expect AI to ease bottlenecks, per Deloitte.

  • Faster approvals could become standard as Massachusetts Gov. Healey proposes prior authorization reforms requiring 24-hour insurer response and eliminating requirements for diabetes patients.

  • Practices may see more transparency as NY Gov. Hochul targets prior authorization and premium hikes in proposed reforms.

  • Medicare claims processing may get an overhaul as CMS seeks vendors for ClaimsCore, a unified platform replacing four legacy systems.

  • Medicare Advantage fraud scrutiny intensifies with Kaiser Permanente agreeing to pay $556M to settle allegations of inflated diagnosis codes.

📈 Business & Tech

  • Digital health investment rebounded to $14.2B in 2025, with AI startups receiving 54% of total funding per Rock Health.

  • Patients gain a new cost-comparison tool as Surescripts and GoodRx launch Script Corner for prescription price transparency.

  • Healthcare M&A activity rose 57% driven by IT-focused deals, per Bain, signaling continued PE interest in healthcare tech.

🩺 Clinical

💡 Marketing & Growth

  • Simpler billing may attract patients as HealthPartners launches a copay-only plan for clearer costs.

  • Pharmaceutical giants test new channels as Lilly and Novo pilot direct-to-employer programs to bypass PBMs and reduce costs.

  • Practices can offer new obesity solutions as Humana partners with Eli Lilly to distribute weight loss drugs via employer-focused programs.

  • Nearly half of New Yorkers couldn't afford a $1,000 medical
    bill, underscoring the need for transparent pricing and payment plans.

⭐ Just for Fun

The Deep Dive

The 2026 growth playbook for independent derm

Most dermatologists think growth means signing a lease. They're wrong.

Medicare's 2025 conversion factor dropped 2.8%. Denial rates climbed to 11.8%, up from 10.2% just two years ago. Meanwhile, private equity keeps circling at 12-15x EBITDA.

Here's the uncomfortable math: 38% of dermatologists are 55 or older. A retirement wave is coming, and practices that don't grow will get absorbed.

But "growth" doesn't mean what most people think.

Cash flow is the foundation

The 5,302 dermatology practices in the U.S. share one thing: their billing departments either enable growth or kill it.

Industry benchmark for A/R is 30-40 days. High performers hit under 30. If you're above 40, you're funding your payers' cash flow, not your own.

The denial problem is worse than most realize: healthcare systems spend $20 billion annually reworking denied claims, at roughly $117 per denial. And only 50-65% of denied claims ever convert to revenue.

Every billing problem you have today gets amplified when you add volume.

Fix capacity before adding footprint

The instinct is backward. Practices see demand and lease space, but the smarter move is fixing what you have first.

35-40 day wait times drive 15-20% patient leakage. Patients who can't get in go somewhere else… or even worse, nowhere at all.

Then there's the no-show problem. 12-30% of appointments go unfilled because patients don't show up. That's capacity you already paid for.

A practice running 25% no-shows doesn't need a second location. It needs better patient communication, tighter scheduling protocols, and real accountability for follow-up.

The provider math has to work

Operating expenses run 72.9-75.1% of net revenues in dermatology. That's before you factor in the cost of recruiting, onboarding, and retaining providers.

Adding a new provider makes sense when they'll be cash-flow positive within a reasonable timeframe. Not when you're hoping volume will materialize. The practices that retain providers long-term do two things: pay transparently and set realistic expectations.

Billing is growth infrastructure

60% of medical groups reported increased denials last year. The clean claim rate benchmark is 95%+. If you're not hitting it, every new patient you add creates another claim that might not get paid.

A/R over 90 days should be under 15% of total. If yours is higher, you're not growing, you're just scaling a collection problem.

Recently, a Midwest practice discovered their previous billing company had been using modifier 52 incorrectly for several years. The result was $700,000 in underpayments. They didn't find it until they switched to a derm-focused biller and gained direct access to the people working their claims.

Transparency isn't a nice-to-have. It's how you catch problems before they become catastrophes.

Fund growth from within

Reimbursement isn't getting better. So where does expansion capital come from?

Operational discipline.

One Clarity client found $110,000 in annual savings by auditing two contracts: long-term disability insurance ($55,000) and medical waste disposal ($55,000). Their previous waste vendor was charging $1,000/month for a single box at one location.

Every contract deserves annual scrutiny. LTD. Waste disposal. Medical supplies. Lab services. Credit card processing. Most practices are overpaying somewhere.

Those savings compound. $110,000/year buys a lot of growth that doesn't require PE terms or debt service.

The retirement opportunity

The overlooked growth play isn't always a new building, it's often the dermatologist down the road who's about to retire.

With 38% of dermatologists over 55, these conversations are everywhere. And the math is favorable: a fair payment for phone numbers, fax numbers, and patient charts buys continuity that patients want and retiring docs need.

When that phone rings, someone calling the number they've dialed for 35 years, they get you. With their chart already scanned. Ready to see them.

No debt. No lease. Established patients from day one.

The PE question

Private equity isn't inherently bad. But it's not the only path, and it comes with trade-offs in autonomy and decision-making that many dermatologists underestimate.

The practices thriving without PE share common traits: disciplined billing, capacity optimization before expansion, provider economics that work, and relentless expense management.

They grow methodically. And they keep control.

Takeaways

  1. Benchmark A/R monthly. Target under 30 days. If you're over 40, fix that before anything else.

  2. Audit your denial rate. Every percentage point costs real revenue. Only 50-65% of denials ever convert.

  3. Maximize existing capacity. A 25% no-show rate is a scheduling problem, not a space problem.

  4. Add providers only when billing can scale. New volume with broken billing just scales your losses.

  5. Run annual expense audits. $110,000 in contract savings funds growth without debt or equity dilution.

  6. Map your market. Know who's retiring within 30 miles. Those conversations should start now.

Bottom line: PE may be circling at 12-15x EBITDA, but independence is still an option. It just requires discipline most practices haven't built yet. 2026 will reward the practices that get this right.

Please note that this is general information, not legal or billing advice. Payer policies vary by plan and state.
Need a pro?

When you're ready for an expert to make your practice's billing bulletproof, schedule a strategy call with our team.

That’s it for this week.

This one was super fun. Hope you enjoyed it too.

What did you think of today's edition?

Login or Subscribe to participate

Reply

or to participate

Keep Reading

No posts found